Since the initial discovery of mutations in the IDH1 by whole-genome sequencing in a large subset of human gliomas [11] and AML patients [12], there has been a focus on understanding the consequences of mutations in IDH genes and their roles in tumor progression. This evidence concerns the gene IDH1 and glioma.